Last reviewed · How we verify
At the discretion of the investigator
At the discretion of the investigator is a Small molecule drug developed by Institut Bergonié. It is currently in Phase 3 development for At the discretion of the investigator.
The mechanism of this drug is not specified.
The mechanism of this drug is not specified. Used for At the discretion of the investigator.
At a glance
| Generic name | At the discretion of the investigator |
|---|---|
| Sponsor | Institut Bergonié |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
At the discretion of the investigator, the exact mechanism of action is not provided.
Approved indications
- At the discretion of the investigator
Common side effects
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas (PHASE1)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (PHASE4)
- Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- At the discretion of the investigator CI brief — competitive landscape report
- At the discretion of the investigator updates RSS · CI watch RSS
- Institut Bergonié portfolio CI
Frequently asked questions about At the discretion of the investigator
What is At the discretion of the investigator?
How does At the discretion of the investigator work?
What is At the discretion of the investigator used for?
Who makes At the discretion of the investigator?
What development phase is At the discretion of the investigator in?
Related
- Manufacturer: Institut Bergonié — full pipeline
- Indication: Drugs for At the discretion of the investigator